Unknown

Dataset Information

0

Phosphomannomutase deficiency (PMM2-CDG): ataxia and cerebellar assessment.


ABSTRACT: Phosphomannomutase deficiency (PMM2-CDG) is the most frequent congenital disorder of glycosylation. The cerebellum is nearly always affected in PMM2-CDG patients, a cerebellar atrophy progression is observed, and cerebellar dysfunction is their main daily functional limitation. Different therapeutic agents are under development, and clinical evaluation of drug candidates will require a standardized score of cerebellar dysfunction. We aim to assess the validity of the International Cooperative Ataxia Rating Scale (ICARS) in children and adolescents with genetically confirmed PMM2-CDG deficiency. We compare ICARS results with the Nijmegen Pediatric CDG Rating Scale (NPCRS), neuroimaging, intelligence quotient (IQ) and molecular data.Our observational study included 13 PMM2-CDG patients and 21 control subjects. Ethical permissions and informed consents were obtained. Three independent child neurologists rated PMM2-CDG patients and control subjects using the ICARS. A single clinician administered the NPCRS. All patients underwent brain MRI, and the relative diameter of the midsagittal vermis was measured. Psychometric evaluations were available in six patients. The Mann-Whitney U test was used to compare ICARS between patients and controls. To evaluate inter-observer agreement in patients' ICARS ratings, intraclass correlation coefficients (ICC) were calculated. ICARS internal consistency was evaluated using Cronbach's alpha. Spearman's rank correlation coefficient test was used to correlate ICARS with NPCRS, midsagittal vermis relative diameter and IQ.ICARS and ICARS subscores differed between patients and controls (p?

SUBMITTER: Serrano M 

PROVIDER: S-EPMC4623922 | biostudies-literature | 2015

REPOSITORIES: biostudies-literature

altmetric image

Publications


<h4>Background</h4>Phosphomannomutase deficiency (PMM2-CDG) is the most frequent congenital disorder of glycosylation. The cerebellum is nearly always affected in PMM2-CDG patients, a cerebellar atrophy progression is observed, and cerebellar dysfunction is their main daily functional limitation. Different therapeutic agents are under development, and clinical evaluation of drug candidates will require a standardized score of cerebellar dysfunction. We aim to assess the validity of the Internati  ...[more]

Similar Datasets

| S-EPMC5602850 | biostudies-other
| S-EPMC7510076 | biostudies-literature
| S-EPMC5855841 | biostudies-literature
| S-EPMC4944953 | biostudies-literature
| S-EPMC8754259 | biostudies-literature
| S-EPMC10733668 | biostudies-literature
| S-EPMC1235268 | biostudies-literature
| S-EPMC8360885 | biostudies-literature
| S-EPMC4824866 | biostudies-literature
| S-EPMC10837865 | biostudies-literature